Introduction The 2011–20 forecast period will see the loss of exclusivity for the leading non-insulin antidiabetic Actos franchise, while new launches include the first once-weekly GLP-1 agonists and the oral SGLT-2 inhibitor class, to compete in an increasingly crowded treatment algorithm in type 2 diabetes. Features and benefits Forecast leading non-insulin antidiabetic brands in the 2011–20 period Quantify the sales potential late-stage pipeline products Assess the impact of generic competition and sales restrictions on the Actos (pioglitazone) franchise Determine the impact of recent clinical trial results and regulatory decisions
Highlights Despite moderate efficacy, a benign safety profile and oral delivery will mean that DPP-IV inhibitors continue to dominate branded non-insulin antidiabetics, with the class forecast to be worth over $7bn in 2020, led by gold standard Januvia. The GLP-1 agonist class will see once-weekly product launch, but doubts about their efficacy will allow once-daily Victoza (liraglutide; Novo Nordisk) to retain a leading position in the class and reach blockbuster status early in the forecast period. The US market for key non-insulin products will decline temporarily after the loss of exclusivity for Actos in August 2012. Use of the product in Europe has been reduced in 2011 due to bladder cancer risk concerns. However, in Japan Takeda’s strong market position and poor generic penetration will mean a substantial revenue stream through 2020. Your key questions answered Use the Datamonitor patient-based forecast to quantify key non-insulin product sales at country, class, molecule and brand levels Identify which brands will grow in the 2011–2020 forecast period and which markets are more receptive to growth Use volume data to understand overriding market trends
Contains 105 pages and 89 tables/figures.
|